Galectin-3 binding protein (LGALS3BP) has been used as a component of a multi-protein panel for the prediction of fibrosis in Hepatitis C (HCV) infection70, and serves as a biomarker of hepatocellular carcinoma resulting from HCV cirrhosis71. This evidence concerns the gene LGALS3BP and hepatocellular carcinoma.